Idelalisib has activity in mantle cell lymphoma. -

Idelalisib has activity in mantle cell lymphoma.

Abstract	The PI3Kδ inhibitor idelalisib was effective in heavily pretreated patients with mantle cell lymphoma.
Authors
Journal	Cancer discovery (Cancer Discov) Vol. 4 Issue 5 Pg. OF8 (May 2014) ISSN: 2159-8290 [Electronic] United States
PMID	24795031 (Publication Type: Journal Article)
Chemical References	Antineoplastic Agents Phosphoinositide-3 Kinase Inhibitors Purines Quinazolinones idelalisib
Topics	Antineoplastic Agents (administration & dosage, therapeutic use) Clinical Trials, Phase I as Topic Dose-Response Relationship, Drug Humans Lymphoma, Mantle-Cell (drug therapy, pathology) Phosphoinositide-3 Kinase Inhibitors Purines (administration & dosage, therapeutic use) Quinazolinones (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!